Sermorelin (GHRH 1-29) — Dosing, Cycles, Half-Life & Side Effects

Sermorelin (GHRH 1-29) is a growth hormone releasing hormone (GHRH) analogue with a half-life of 10-20 minutes. Bioidentical GHRH fragment (first 29 amino acids) that stimulates natural pulsatile GH release. FDA-approved for GH deficiency diagnosis and previously for pediatric GH deficiency treatment. This page is educational harm-reduction reference compiled from peer-reviewed literature — not medical advice, not an endorsement, not a recommendation to use. Consult a licensed clinician before any decision.

Quick Facts

ClassGrowth Hormone Releasing Hormone
Half-life10-20 minutes
HepatotoxicityNone
Suppression0/10

Typical Dosing Ranges

Common dose range: 100-300mcg before bed

Cycle length: 12-26 weeks (long-term use acceptable)

Dose ranges are compiled from published pharmacokinetic studies and community-reported usage. Where a value is community-reported rather than clinically studied, this page and its structured data flag it. Lower end of any range is always the safer starting point.

Stacking Considerations

  • No structural stacking blockers. Standard harm-reduction rules apply: minimize total androgen load, minimize oral exposure, and monitor bloodwork.

PCT Requirements

  • Never stack two SERMs. Extend a single SERM (tamoxifen OR enclomiphene/clomiphene) rather than combining.
  • Use the cycle planner to generate a full protocol based on your complete stack, not this compound alone.

Side Effect Profile

  • Very short half-life
  • Requires nightly injection
  • Results take 3-6 months to manifest
  • Less potent than modified analogs

Known Interactions

No compound-specific interactions are catalogued in the current matrix. This does not mean no risk exists — it means there is no curated pairwise entry.

Monitoring (Bloodwork & Vitals)

  • Comprehensive metabolic panel (baseline, mid-cycle, post-cycle)
  • Lipid panel (total cholesterol, HDL, LDL, triglycerides)
  • CBC (hemoglobin, hematocrit — watch for erythrocytosis)
  • Sex-hormone panel (Total T, Free T, Estradiol sensitive, SHBG, LH, FSH)
  • Blood pressure (weekly self-check; flag systolic >140 or diastolic >90)

Baseline bloodwork is recommended before any cycle. Discontinue if liver enzymes exceed 3× upper limit of normal or if hematocrit exceeds 54%.

Frequently Asked Questions

What is the half-life of Sermorelin (GHRH 1-29)?

Sermorelin (GHRH 1-29) has a half-life of approximately 10-20 minutes. This figure is used to determine injection frequency (for esters) and post-cycle clearance timing.

What is the typical dose range for Sermorelin (GHRH 1-29)?

Commonly reported ranges for Sermorelin (GHRH 1-29): 100-300mcg before bed. Cycle length: 12-26 weeks (long-term use acceptable). These are compiled from published studies and community-reported usage — individual response varies and lower end is always preferred.

Does Sermorelin (GHRH 1-29) suppress natural testosterone?

Sermorelin (GHRH 1-29) causes minimal suppression of the HPTA axis (score 0/10). PCT may still be advisable depending on stack and duration.

What is Sermorelin (GHRH 1-29) typically used for?

Sermorelin (GHRH 1-29) is commonly used for: Anti-aging protocols, Recovery enhancement, Sleep improvement. Intended-use context does not imply safety — every use case carries the same underlying pharmacological risks.

Is Sermorelin (GHRH 1-29) legal?

Sermorelin (GHRH 1-29) is a controlled substance in many jurisdictions (typically Schedule III in the US when it is an anabolic androgenic steroid). StackItSmart does not provide sourcing information. Possession, import, and use without a prescription carry legal consequences that vary by country and state.

Citations

  1. FDA NDA 20-443. 1997. FDA prescribing information — FDA-approved 1990 diagnostic, 1997 therapeutic; half-life 11-12 minutes

Disclaimer

StackItSmart is an independent harm-reduction reference. The content above is compiled from peer-reviewed literature and is not medical advice, not an endorsement, and not a recommendation to use Sermorelin (GHRH 1-29). Performance-enhancing compounds carry legal, endocrine, cardiovascular, and hepatic risks. Consult a licensed clinician before any decision. StackItSmart does not provide sourcing, procurement, or dosing prescriptions.

Skip to main content